New Frontier Bio

About New Frontier Bio

New Frontier Bio, established in 2020, is a biotechnology firm focused on the consumer health market, operating out of Beverly, Massachusetts. The company applies principles from biotechnology and pharmaceuticals to identify, optimize, and commercialize natural compounds aimed at improving human health and longevity. Its business model centers on creating and selling a portfolio of consumer health products, including a skincare line and supplements designed to address the cellular mechanisms of aging. Revenue is generated through direct-to-consumer sales, including a subscription-based auto-refill program for its products, marketed under brands like Aramore Skincare.

The company was founded by seasoned life science entrepreneurs and is supported by scientific co-founders from Harvard and MIT who are leaders in cutaneous biology, natural chemistry, and longevity. The management team includes Chairman Steven Kennedy Smith, who has a background with the Kennedy Family Office and co-founding Pear Therapeutics, and COO & President Kevin Kong, a Doctor of Pharmacy with experience in biotech investment and healthcare operations. The leadership team is further strengthened by scientific co-founders Anna Mandinova, Brad Pentelute, and Sarina Elmariah, and a board of strategic advisors with expertise from institutions like DARPA and the Harvard Stem Cell Institute.

New Frontier Bio's product development is grounded in scientific research to create new combinations of natural compounds that work synergistically to activate cellular regenerative functions. The initial product pipeline includes a skin health and supplement line based on a natural compound showing potential benefits against various mechanisms of human aging. The company's products, such as those under the Aramore brand, are formulated with the intention of reversing signs of aging and promoting health from the cellular level. The firm has actively sought funding to expand its operations and accelerate product development, including a $12 million equity investment round in 2022 and a $2 million debt financing effort in 2024.